Media coverage
29Media coverage
Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Reuters Country United Kingdom Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Yahoo! Finance Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet PharmiWeb Country United Kingdom Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Town Hall Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Vision Monday Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Marketplace Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Industrial Info Financials Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet CEOWorld Magazine Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet RCL Advisors Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Wall Street Business Network Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Crawford Financial Planning Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Market Pulse Navigator Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet MoneyShow.com Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Fat Pitch Financials Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Reliance Trust Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Franklin Credit Management Corporation Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet BioSpace Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet A.M. Best Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet SearchBug Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Yahoo! 7 Finance Country Australia Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet 4 Traders Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Tamar Securities Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Financial Content Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Virtual Strategy Magazine Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet U-T San Diego Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Good Day Sacramento Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet Ask.com Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet GlobeNewswire Country United States Date 9/17/15 Persons Andrew Brenner Title VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference Media name/outlet BizWire Express Country India Date 9/17/15 Persons Andrew Brenner